SAN FRANCISCO — Unlearn®, a pioneer in artificial intelligence for clinical trials, has appointed Kwame Marfo as its first Vice President of Product, marking a significant step in the company’s expansion and strategic growth. Marfo will lead product strategy and development efforts as Unlearn continues to scale its digital twin technology, which aims to accelerate drug development and improve clinical trial efficiency.
“Kwame brings the rare combination of deep domain expertise and a sharp product mindset that will be invaluable as we continue to scale,” said Steve Herne, CEO of Unlearn. “His experience improving trial design and execution aligns closely with our mission to accelerate research through digital twin technology and will further position Unlearn as a market leader reshaping clinical trial design and execution.”
Marfo joins the company with over 15 years of experience at the intersection of life sciences, health technology, and product innovation. Most recently, he served as Senior Director of Product Strategy and Incubation at Komodo Health, where he led cross-functional teams across clinical development and medical affairs. He previously spent more than a decade at Genentech, holding leadership roles in global clinical operations and manufacturing sciences. As Director of Insights & Analytics at Genentech, he co-founded a unit that became central to advancing trial strategy, improving patient representation, and accelerating timelines.
“Unlearn is tackling one of the most longstanding challenges in healthcare by modernizing clinical trials and helping bring effective treatments to patients faster,” said Marfo. “I’m excited to join a team that’s not only leading in AI innovation, but also rethinking legacy systems with a deep commitment to scientific rigor and real-world patient impact.”
Marfo holds a bachelor’s degree in chemical engineering from Stanford University and an MBA from UC Berkeley’s Haas School of Business. His appointment signals Unlearn’s deepening investment in product development as it seeks to transform the clinical trial landscape through artificial intelligence.
